JP7846091B2 - 複素環式化合物およびその使用 - Google Patents

複素環式化合物およびその使用

Info

Publication number
JP7846091B2
JP7846091B2 JP2023513975A JP2023513975A JP7846091B2 JP 7846091 B2 JP7846091 B2 JP 7846091B2 JP 2023513975 A JP2023513975 A JP 2023513975A JP 2023513975 A JP2023513975 A JP 2023513975A JP 7846091 B2 JP7846091 B2 JP 7846091B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
alkyl
heterocycloalkyl
cycloalkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023513975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540270A5 (cg-RX-API-DMAC7.html
JP2023540270A (ja
Inventor
イー リウ,
ピンダ レン,
リアンシェン リー,
ジミン ジュー,
シウウェン ジュー,
Original Assignee
カムクワット バイオサイエンシーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カムクワット バイオサイエンシーズ インコーポレイテッド filed Critical カムクワット バイオサイエンシーズ インコーポレイテッド
Publication of JP2023540270A publication Critical patent/JP2023540270A/ja
Publication of JP2023540270A5 publication Critical patent/JP2023540270A5/ja
Priority to JP2026061261A priority Critical patent/JP2026099899A/ja
Application granted granted Critical
Publication of JP7846091B2 publication Critical patent/JP7846091B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
JP2023513975A 2020-08-28 2021-08-27 複素環式化合物およびその使用 Active JP7846091B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026061261A JP2026099899A (ja) 2020-08-28 2026-04-02 複素環式化合物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063072056P 2020-08-28 2020-08-28
US63/072,056 2020-08-28
PCT/US2021/048101 WO2022047260A1 (en) 2020-08-28 2021-08-27 Heterocyclic compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026061261A Division JP2026099899A (ja) 2020-08-28 2026-04-02 複素環式化合物およびその使用

Publications (3)

Publication Number Publication Date
JP2023540270A JP2023540270A (ja) 2023-09-22
JP2023540270A5 JP2023540270A5 (cg-RX-API-DMAC7.html) 2024-09-04
JP7846091B2 true JP7846091B2 (ja) 2026-04-14

Family

ID=80353317

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023513975A Active JP7846091B2 (ja) 2020-08-28 2021-08-27 複素環式化合物およびその使用
JP2026061261A Pending JP2026099899A (ja) 2020-08-28 2026-04-02 複素環式化合物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026061261A Pending JP2026099899A (ja) 2020-08-28 2026-04-02 複素環式化合物およびその使用

Country Status (7)

Country Link
US (2) US12365676B2 (cg-RX-API-DMAC7.html)
EP (1) EP4203952A4 (cg-RX-API-DMAC7.html)
JP (2) JP7846091B2 (cg-RX-API-DMAC7.html)
CN (1) CN116368130A (cg-RX-API-DMAC7.html)
AU (1) AU2021331492A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191279A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022047260A1 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
CA3191279A1 (en) 2020-08-28 2022-03-03 Yi Liu Heterocyclic compounds and uses thereof
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
JP2024505594A (ja) * 2021-02-09 2024-02-06 メッドシャイン ディスカバリー インコーポレイテッド ピリミジン芳香環化合物
CN117715915A (zh) * 2021-04-09 2024-03-15 杭州英创医药科技有限公司 作为kras g12d抑制剂的杂环化合物
WO2022232331A1 (en) * 2021-04-29 2022-11-03 Amgen Inc. Heterocyclic compounds and methods of use
EP4329888A1 (en) * 2021-04-29 2024-03-06 Amgen Inc. 2-aminobenzothiazole compounds and methods of use thereof
EP4332105A4 (en) * 2021-04-30 2025-05-28 Genfleet Therapeutics (Shanghai) Inc. PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS MEDICAL USE
CN117500799A (zh) * 2021-06-09 2024-02-02 伊莱利利公司 作为kras g12d抑制剂的取代的稠合吖嗪
WO2022258974A1 (en) * 2021-06-10 2022-12-15 Redx Pharma Plc Quinazoline derivatives useful as ras inhibitiors
CA3227138A1 (en) 2021-07-23 2023-01-26 Theras, Inc. Compositions and methods for inhibition of ras
WO2023039240A1 (en) * 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023061294A1 (zh) * 2021-10-13 2023-04-20 再鼎医药(上海)有限公司 含氮杂环类衍生物调节剂、其制备方法及应用
WO2023072188A1 (zh) * 2021-10-29 2023-05-04 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
EP4405337A4 (en) * 2021-11-30 2025-11-26 Beta Pharma Inc Fused pyrimidine derivatives as kras oncoprotein inhibitors
IL314486A (en) * 2022-02-03 2024-09-01 Mirati Therapeutics Inc Quinazoline compounds inhibit PAN-KRAS
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
CN118715215A (zh) * 2022-02-16 2024-09-27 美国安进公司 作为突变kras蛋白抑制剂的喹唑啉化合物及其用途
JP2025508702A (ja) * 2022-02-16 2025-04-10 アムジエン・インコーポレーテツド キナゾリン化合物、及び変異krasタンパク質の阻害剤としてのその使用
WO2023172737A1 (en) 2022-03-11 2023-09-14 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
JP2025510656A (ja) * 2022-03-24 2025-04-15 ベイジーン スウィッツァーランド ゲーエムベーハー 複素環式化合物、その組成物、及びそれらを用いた治療方法
WO2023183585A1 (en) * 2022-03-25 2023-09-28 Eli Lilly And Company Kras inhibitors
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔5,4-b〕吡啶malt-1抑制劑
US20240116951A1 (en) * 2022-05-04 2024-04-11 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
WO2024008179A1 (en) * 2022-07-07 2024-01-11 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2024041621A1 (en) * 2022-08-25 2024-02-29 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024056063A1 (zh) * 2022-09-16 2024-03-21 南京明德新药研发有限公司 含六氢螺环[环丙烷-1,2'-吡咯嗪]的化合物
WO2024061365A1 (zh) * 2022-09-22 2024-03-28 成都奥睿药业有限公司 嘧啶并环类化合物及其制备方法与用途
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
EP4680609A1 (en) 2023-03-15 2026-01-21 Quanta Therapeutics, Inc. Kras modulators and uses thereof
PE20252444A1 (es) * 2023-03-31 2025-10-20 Lilly Co Eli Inhibidores de kras
EP4735451A1 (en) 2023-06-30 2026-05-06 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054977A1 (en) 2002-12-13 2004-07-01 Cytopia Pty Ltd Nicotinamide-based kinase inhibitors
JP2016532656A (ja) 2013-10-10 2016-10-20 アラクセス ファーマ エルエルシー Krasg12cの阻害剤
JP2020521742A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー Krasの共有結合性阻害剤

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW212792B (cg-RX-API-DMAC7.html) * 1991-09-13 1993-09-11 Shell Internat Res Schappej B V
US20090069300A1 (en) * 2007-09-12 2009-03-12 Wyeth Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists
WO2012154760A1 (en) * 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
WO2013155223A1 (en) 2012-04-10 2013-10-17 The Regents Of The University Of California Compositions and methods for treating cancer
WO2014160200A1 (en) 2013-03-13 2014-10-02 Dana-Farber Cancer Institute, Inc. Ras inhibitors and uses thereof
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Kras g12c之抑制劑
US9862701B2 (en) 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
AU2016245864C1 (en) * 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
ES2856880T3 (es) 2015-04-15 2021-09-28 Araxes Pharma Llc Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
WO2016176338A1 (en) 2015-04-30 2016-11-03 The Trustees Of Columbia University In The City Of New York Small molecule ras ligands
AU2016258192B2 (en) 2015-05-06 2021-07-29 Leidos Biomedical Research, Inc. K-Ras modulators
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
KR102932353B1 (ko) 2015-11-16 2026-02-27 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
JP2019529484A (ja) 2016-09-29 2019-10-17 アラクセス ファーマ エルエルシー Kras g12c変異体タンパク質の阻害剤
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
AU2017378393B2 (en) 2016-12-14 2023-03-09 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
EP3558979B1 (en) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
JOP20190186A1 (ar) 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
CA3056970A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
US11047054B2 (en) 2017-04-19 2021-06-29 California Institute Of Technology Oxygen evolution reaction catalysis
US11358940B2 (en) * 2017-04-20 2022-06-14 The Regents Of The University Of California K-Ras modulators
WO2018206539A1 (en) 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
TW201906832A (zh) 2017-05-25 2019-02-16 美商亞瑞克西斯製藥公司 用於癌症治療之化合物及其使用方法
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
CA3082579A1 (en) 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3718514A4 (en) 2017-11-29 2021-07-28 Bridgestone Corporation RUBBER COMPOSITION FOR A PROSTHESIS FOOT SOLE AND PROSTHESIS FOOT SOLE
WO2019104505A1 (zh) 2017-11-29 2019-06-06 中车资阳机车有限公司 一种用于油--电混合动力机车车载动力电池的充电系统
PL3728254T3 (pl) 2017-12-21 2023-06-12 Boehringer Ingelheim International Gmbh Benzyloaminopodstawione pirydopirymidynony i pochodne jako inhibitory sos1
SG10202102462SA (en) 2018-01-19 2021-04-29 Medshine Discovery Inc Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
WO2019204442A1 (en) 2018-04-18 2019-10-24 Theras, Inc. K-ras modulators with a cyanoacrylamide moiety
TW202012371A (zh) 2018-04-18 2020-04-01 美商德洛斯股份有限公司 具乙烯碸部分之k-ras調節劑
EP3781565A1 (en) 2018-04-18 2021-02-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
EP3788053B1 (en) 2018-05-04 2024-07-10 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
WO2019217691A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
JP2021176820A (ja) 2018-07-31 2021-11-11 アステラス製薬株式会社 キナゾリン化合物を有効成分とする医薬組成物
JP2021176819A (ja) 2018-07-31 2021-11-11 アステラス製薬株式会社 キナゾリン化合物を有効成分とする医薬組成物
CN112119075B (zh) 2018-08-16 2024-03-12 豪夫迈·罗氏有限公司 稠环化合物
ES2961253T3 (es) 2018-08-31 2024-03-11 Mirati Therapeutics Inc Inhibidores de KRas G12C
AR116604A1 (es) * 2018-10-15 2021-05-26 Lilly Co Eli Inhibidores de kras g12c
WO2020097537A2 (en) 2018-11-09 2020-05-14 Genentech, Inc. Fused ring compounds
EP3887373A1 (en) 2018-11-29 2021-10-06 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
US20230096028A1 (en) 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
CN113874374B (zh) 2019-05-24 2024-12-27 江苏恒瑞医药股份有限公司 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
CN112300153B (zh) 2019-07-26 2023-06-13 博瑞生物医药(苏州)股份有限公司 一种杂环化合物、药物组合物和用途
US20210040089A1 (en) 2019-08-07 2021-02-11 Jacobio Pharmaceuticals Co., Ltd. Kras mutant protein inhibitors
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
PH12022551102A1 (en) 2019-11-08 2023-11-20 Revolution Medicines Inc Bicyclic heteroaryl compounds and uses thereof
CR20220258A (es) 2019-12-11 2022-07-03 Lilly Co Eli Inhibidores de kras g12c
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
TW202144349A (zh) 2020-04-30 2021-12-01 大陸商上海科州藥物研發有限公司 作為kras抑制劑的雜環化合物的製備及其應用方法
CA3191279A1 (en) 2020-08-28 2022-03-03 Yi Liu Heterocyclic compounds and uses thereof
CN114380827A (zh) 2020-10-22 2022-04-22 贝达药业股份有限公司 Kras g12c抑制剂及其在医药上的应用
WO2022105859A1 (en) 2020-11-20 2022-05-27 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
CN113999226B (zh) 2020-12-22 2023-01-06 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
WO2022135470A1 (zh) 2020-12-22 2022-06-30 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
WO2022148422A1 (en) 2021-01-08 2022-07-14 Beigene, Ltd. Bridged compounds as kras g12d inhibitor and degrader and the use thereof
WO2022170999A1 (zh) 2021-02-09 2022-08-18 南京明德新药研发有限公司 吡啶[4,3-d]嘧啶类化合物
JP2024505594A (ja) 2021-02-09 2024-02-06 メッドシャイン ディスカバリー インコーポレイテッド ピリミジン芳香環化合物
AU2022220678A1 (en) 2021-02-09 2023-09-21 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
MX2023008463A (es) 2021-02-16 2023-12-07 Leidos Biomedical Res Inc Composiciones y métodos para la inhibición del gen del virus de sarcoma de rata kirsten (kras).
WO2022184178A1 (en) 2021-03-05 2022-09-09 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
US20240239788A1 (en) 2021-04-16 2024-07-18 Merck Sharp & Dohme Llc Small molecule inhibitors of kras g12d mutant
CN115490709A (zh) 2021-04-30 2022-12-20 四川海思科制药有限公司 一种krasg12d抑制剂及其在医药上的应用
US20240300980A1 (en) 2021-05-22 2024-09-12 Shanghai Kechow Pharma, Inc. Heterocyclic compounds as kras inhibitor, and preparation therefor and use thereof in treatment
CN117500799A (zh) 2021-06-09 2024-02-02 伊莱利利公司 作为kras g12d抑制剂的取代的稠合吖嗪
WO2022258974A1 (en) 2021-06-10 2022-12-15 Redx Pharma Plc Quinazoline derivatives useful as ras inhibitiors
CA3221608A1 (en) 2021-06-14 2022-12-22 Kumquat Biosciences Inc. Fused heteroaryl compounds useful as anticancer agents
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
CN115611923A (zh) 2021-07-12 2023-01-17 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
CA3227138A1 (en) 2021-07-23 2023-01-26 Theras, Inc. Compositions and methods for inhibition of ras
EP4384522A1 (en) 2021-08-10 2024-06-19 Erasca, Inc. Selective kras inhibitors
WO2023020519A1 (en) 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. 1, 4-oxazepane derivatives and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054977A1 (en) 2002-12-13 2004-07-01 Cytopia Pty Ltd Nicotinamide-based kinase inhibitors
JP2016532656A (ja) 2013-10-10 2016-10-20 アラクセス ファーマ エルエルシー Krasg12cの阻害剤
JP2020521742A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー Krasの共有結合性阻害剤

Also Published As

Publication number Publication date
EP4203952A4 (en) 2024-12-11
CA3191279A1 (en) 2022-03-03
US12365676B2 (en) 2025-07-22
AU2021331492A1 (en) 2023-04-13
EP4203952A1 (en) 2023-07-05
US20230331717A1 (en) 2023-10-19
US12286427B2 (en) 2025-04-29
JP2023540270A (ja) 2023-09-22
CN116368130A (zh) 2023-06-30
WO2022047260A1 (en) 2022-03-03
JP2026099899A (ja) 2026-06-18
US20240383888A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
US12365676B2 (en) Heterocyclic compounds and uses thereof
US11648254B2 (en) Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling
US20240270736A1 (en) Macrocyclic heterocycles and uses thereof
WO2025059366A1 (en) Ras inhibitors
TW202523326A (zh) 雜環及其用途
JP2025525946A (ja) 複素環式化合物およびその使用
EP4519274A1 (en) Heterocyclic compounds and uses thereof
JP2024521473A (ja) 抗がん剤として有用な縮合ヘテロアリール化合物
JP2026502159A (ja) 複素環およびその使用
JP2024506329A (ja) 複素環式化合物およびその使用
TW202502779A (zh) 取代的雜芳族胺及其用途
TWI724056B (zh) Cxcr2抑制劑
WO2023141300A1 (en) Heterocyclic compounds and uses thereof
WO2022081912A2 (en) Heterocycles and uses thereof
WO2023215802A1 (en) Heterocyclic compounds and uses thereof
AU2017277833B2 (en) 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer
KR102811956B1 (ko) 암을 치료하기 위한 1-(피페리디노카보닐메틸)-2-옥소피페라진 유도체
KR20250004810A (ko) 대환식 헤테로환 및 이의 용도
JP2021501785A (ja) 統合的ストレス経路の調節剤
WO2022271562A1 (en) Heterocycles and uses thereof
CN117794940A (zh) 用作抗癌药剂的稠合杂芳基化合物
TW202438056A (zh) 雜環化合物及其用途
TW202434589A (zh) 巨環雜環及其用途
BR112018009880B1 (pt) Compostos e composições farmacêuticas moduladores dos receptores de quimiocina e seus usos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240827

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260402

R150 Certificate of patent or registration of utility model

Ref document number: 7846091

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150